AU2001268373A1 - Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus - Google Patents
Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virusInfo
- Publication number
- AU2001268373A1 AU2001268373A1 AU2001268373A AU6837301A AU2001268373A1 AU 2001268373 A1 AU2001268373 A1 AU 2001268373A1 AU 2001268373 A AU2001268373 A AU 2001268373A AU 6837301 A AU6837301 A AU 6837301A AU 2001268373 A1 AU2001268373 A1 AU 2001268373A1
- Authority
- AU
- Australia
- Prior art keywords
- associated virus
- adeno
- methods
- previously exposed
- virions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000702421 Dependoparvovirus Species 0.000 title 2
- 210000002845 virion Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21106600P | 2000-06-13 | 2000-06-13 | |
| US60211066 | 2000-06-13 | ||
| PCT/US2001/018965 WO2001096587A2 (en) | 2000-06-13 | 2001-06-13 | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001268373A1 true AU2001268373A1 (en) | 2001-12-24 |
Family
ID=22785464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001268373A Abandoned AU2001268373A1 (en) | 2000-06-13 | 2001-06-13 | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20020106381A1 (en) |
| AU (1) | AU2001268373A1 (en) |
| WO (1) | WO2001096587A2 (en) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1379134A4 (en) * | 2001-03-14 | 2006-04-05 | Genteric Inc | Recombinant adeno-assocaited virus-mediated gene transfer via retroductal infusion of virions |
| US20040009151A1 (en) * | 2002-04-04 | 2004-01-15 | Kay Mark A. | Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal |
| GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
| CA2602793C (en) * | 2005-04-13 | 2016-11-22 | Astrazeneca Ab | A host cell comprising a vector for production of proteins requiring gamma-carboxylation |
| AU2007277392A1 (en) * | 2006-07-25 | 2008-01-31 | Celladon Corporation | Extended antegrade epicardial coronary infusion of adeno-associated viral vectors for gene therapy |
| US8206967B2 (en) | 2007-07-06 | 2012-06-26 | Medimmune Limited | Method for production of recombinant human thrombin |
| WO2009105135A1 (en) | 2008-02-19 | 2009-08-27 | Celladon Corporation | Compositions for enhanced uptake of viral vectors in the myocardium |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| BR112017009497A2 (en) | 2014-11-05 | 2018-02-06 | Voyager Therapeutics, Inc. | aadc polynucleotides for the treatment of parkinson's disease |
| SG10202001102XA (en) | 2014-11-14 | 2020-03-30 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| RU2020108189A (en) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | COMPOSITIONS AND METHODS OF TREATMENT OF LATERAL AMYOTROPHIC SCLEROSIS (ALS) |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| EP3384035A4 (en) | 2015-12-02 | 2019-08-07 | Voyager Therapeutics, Inc. | Assays for the detection of aav neutralizing antibodies |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11951121B2 (en) | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
| IL302748A (en) | 2016-05-18 | 2023-07-01 | Voyager Therapeutics Inc | modulatory polynucleotides |
| EP3831281A1 (en) | 2016-08-30 | 2021-06-09 | The Regents of The University of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
| CN119491003A (en) | 2017-05-05 | 2025-02-21 | 沃雅戈治疗公司 | Compositions and methods for treating huntington's disease |
| WO2018204786A1 (en) | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| EP3654860A1 (en) | 2017-07-17 | 2020-05-27 | Voyager Therapeutics, Inc. | Trajectory array guide system |
| KR20200044793A (en) | 2017-08-03 | 2020-04-29 | 보이저 테라퓨틱스, 인크. | Compositions and methods for delivery of AAV |
| MX2020003042A (en) | 2017-09-29 | 2020-11-18 | Voyager Therapeutics Inc | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery. |
| EP3697908A1 (en) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| TW202413649A (en) | 2017-10-16 | 2024-04-01 | 美商航海家醫療公司 | Treatment of amyotrophic lateral sclerosis (als) |
| MX2021002041A (en) * | 2018-08-30 | 2021-07-21 | Res Inst Nationwide Childrens Hospital | Gene therapy for the treatment of galactosemia. |
| KR20210068068A (en) | 2018-09-28 | 2021-06-08 | 보이저 테라퓨틱스, 인크. | Prataxin expression constructs with engineered promoters and methods of use thereof |
| WO2022026410A2 (en) | 2020-07-27 | 2022-02-03 | Voyager Therapeutics, Inc | Compositions and methods for the treatment of niemann-pick type c1 disease |
| AU2021315876A1 (en) | 2020-07-27 | 2023-02-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2023091949A2 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| WO2024163012A1 (en) | 2023-02-02 | 2024-08-08 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268213B1 (en) * | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| DE69431106T2 (en) * | 1993-05-10 | 2003-05-08 | The Regents Of The University Of Michigan, Ann Arbor | GENTE TRANSFER TO PANCREATIC EPITHELIC CELLS |
| US20010009904A1 (en) * | 1997-12-30 | 2001-07-26 | Jon A. Wolff | Process of delivering a polynucleotide to a cell via the vascular system |
| US5858351A (en) * | 1996-01-18 | 1999-01-12 | Avigen, Inc. | Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors |
| WO1998011244A2 (en) * | 1996-09-11 | 1998-03-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Aav4 vector and uses thereof |
| AU5588298A (en) * | 1996-12-02 | 1998-06-29 | Cell Genesys, Inc. | Adeno-associated viral vector-mediated delivery of dna to cells of the liver |
| AU745386B2 (en) * | 1997-03-14 | 2002-03-21 | Children's Hospital Of Philadelphia, The | Methods and compositions for use in gene therapy for treatment of hemophilia |
| US6156303A (en) * | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| US6200560B1 (en) * | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| EP1379134A4 (en) * | 2001-03-14 | 2006-04-05 | Genteric Inc | Recombinant adeno-assocaited virus-mediated gene transfer via retroductal infusion of virions |
-
2001
- 2001-06-13 US US09/880,702 patent/US20020106381A1/en not_active Abandoned
- 2001-06-13 WO PCT/US2001/018965 patent/WO2001096587A2/en active Application Filing
- 2001-06-13 AU AU2001268373A patent/AU2001268373A1/en not_active Abandoned
-
2005
- 2005-02-23 US US11/065,117 patent/US20050281784A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001096587A8 (en) | 2002-04-04 |
| WO2001096587A2 (en) | 2001-12-20 |
| US20050281784A1 (en) | 2005-12-22 |
| WO2001096587A3 (en) | 2002-05-16 |
| US20020106381A1 (en) | 2002-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001268373A1 (en) | Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus | |
| HUP0103908A3 (en) | Novel infulenza virus vaccine composition | |
| LU91326I2 (en) | Human papillomavirus vaccine Ä6,11,16,18Ü (recombinant, adsorbed) | |
| AU2001282528A1 (en) | Compounds having anti-hepatitis c virus effect | |
| GB2366693B (en) | Software virus protection | |
| DK1210113T3 (en) | Combined vaccine preparations | |
| ID30459A (en) | MACROSICLIC PEPTIDES ACTIVE AGAINST HEPATITIS VIRUS C | |
| GB2337755B (en) | Virus vaccine | |
| ATE490327T1 (en) | VACCINE COMPOSITION | |
| AU1775901A (en) | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders | |
| AU2002222118A1 (en) | Pharmaceutical compositions for inhalation | |
| IL155073A0 (en) | Split enveloped virus preparation | |
| AU2002220460A1 (en) | The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits | |
| IL158428A0 (en) | Vaccine composition comprising at least one hiv virus antigen | |
| IL153879A0 (en) | Modified virus | |
| AU2002237195A1 (en) | Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus | |
| NO20033829L (en) | Virus killing preparations | |
| AU2002233220A1 (en) | Medicament for preventing or treating tumors caused by human papilloma virus type 18 | |
| AU2002322082A1 (en) | Pharmaceutical composition for the treatment of viral infection | |
| AU4445201A (en) | Method for administering insulin to the buccal region | |
| AU2002215114A1 (en) | Pharmaceutical compositions for inhalation | |
| AU2002239462A1 (en) | Compositions for protection against bovine viral diseases | |
| AU2001229677A1 (en) | Recombinant rhabdoviruses as live-viral vaccines for immunodeficiency viruses | |
| AU7257101A (en) | Influenza virus binding, sialylated oligosaccharide substance and use thereof | |
| IL151188A0 (en) | Medicament for viral diseases |